A blood analyzer and analysis method
By combining fluorescent staining and hemolysis in the leukocyte measurement channel, reticulocytes and large platelets are identified using light scattering and fluorescence signals. This solves the problem of existing technologies being unable to distinguish between mature erythrocytes and reticulocytes, enabling precise classification and counting, and reducing detection costs.
Patent Information
- Application Number
- CN202311839925.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-04-28
- Filing Date
- 2019-04-26
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2039-04-26
AI Technical Summary
Existing blood analyzers cannot distinguish between mature red blood cells and reticulocytes in the white blood cell measurement channel, and designing a separate detection channel increases the cost of instruments and reagents.
Reticulocyte detection is performed using a white blood cell measurement channel. By combining light scattering and fluorescence signals with blood samples after fluorescence staining and hemolysis, reticulocytes and large platelets are identified, and blood shadow region data is used for more precise classification and counting.
It enables accurate differentiation and counting of reticulocytes and large platelets without increasing the number of detection channels, reducing detection costs and improving detection accuracy.
Smart Images

Figure CN117825345B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a blood analyzer and its analysis method. Background Technology
[0002] Blood cells are divided into three types: red blood cells (RBC), white blood cells (WBC), and platelets (PLT). A routine blood test often requires testing the white blood cell count, red blood cell count, and platelet count.
[0003] The detection of white blood cells in blood generally requires hemolysis of the blood cells, followed by detection using flow cytometry or impedance spectroscopy. For example, the process of detecting white blood cells using flow cytometry involves hemolyzing the blood sample, breaking down red blood cells into fragments. The hemolyzed sample is then subjected to flow cytometry to detect the scattered light from the cell particles, and white blood cells are distinguished based on the intensity of the scattered light. Because red blood cells are broken down into smaller fragments, they are less easily detected during the process, thus reducing interference from red blood cells when identifying white blood cells.
[0004] For counting red blood cells and platelets, most medical particle analyzers (including blood cell analyzers) currently use the micropore impedance principle (hereinafter referred to as the impedance method) for detection. The basic principle of the impedance method is Coulter's principle. The typical detection process is as follows: when particles suspended in an electrolyte pass through a detection micropore, the equivalent resistance at the micropore changes. Under the action of a constant current source on both sides of the micropore, the voltage across the micropore changes. This voltage change is collected by the circuit system and forms a voltage pulse waveform. The height of the pulse waveform reflects the cell size, characterizing the particle volume information. Therefore, the instrument provides the volume distribution of the detected particles, i.e., a volume distribution histogram. Analyzing the cell volume histogram allows for cell classification and counting operations, where larger cells are identified as red blood cells and smaller cells are identified as platelets.
[0005] However, electrical impedance tomography (EIT) cannot distinguish between mature erythrocytes and reticulocytes (RET) in erythrocyte identification results, let alone differentiate between reticulocytes at different stages of maturity. Current research suggests that reticulocytes, as an important stage in the erythrocyte maturation process, should also be given due attention.
[0006] Reticulocytes (RETs) are transitional cells between late erythroblasts and mature erythrocytes, slightly larger than mature erythrocytes. Reticulocytes are nucleated erythrocytes that have just lost their nuclei and are still not fully mature. Their cytoplasm contains basophilic substances such as ribosomes and ribonucleic acid. After being stained with brilliant cresyl blue or neomethylene blue, blue or blue-green punctate or even reticular structures can be seen in the cytoplasm, hence the name reticulocyte.
[0007] In recent years, instruments for RET counting using flow cytometry have emerged. The testing method involves staining RETs with dyes and detecting them using principles such as sheath flow technology and radio frequency technology. For example, Chinese patent CN 97110727 discloses a flow cytometry method that can determine reticulocytes by measuring forward scattered light intensity and fluorescence intensity. Because this detection method has advantages such as good repeatability, high accuracy, and time saving, it is being adopted by an increasing number of hospitals.
[0008] However, current flow cytometry analysis for reticulocyte detection requires a separate detection channel in the cell analyzer, which increases the cost of instruments and reagents. Summary of the Invention
[0009] This invention proposes a novel detection method for reticulocytes.
[0010] According to the first aspect, one embodiment provides a blood analyzer, comprising:
[0011] A sample preparation component is used to prepare a test sample. The sample preparation component includes at least a reaction chamber, which provides a place for mixing and incubating the blood sample to be tested, a fluorescent staining agent, and a hemolysin. The mixing and incubation causes the red blood cells in the blood sample to lyse and stains the cell particles in the sample.
[0012] The flow chamber is used to provide a region for individual cell particles in the sample to pass through and receive light;
[0013] The measuring component includes a light source and a light detection device. The light source is used to emit a light beam that illuminates the flow chamber. The light detection device is used to receive the scattered light and fluorescence of cell particles under light irradiation and output the scattered light information and fluorescence information. The scattered light signal includes at least first angle scattered light information, which is used to reflect the size information of the cell particles.
[0014] A data processor is used to identify reticulin particles based on the first angle of scattered light information and fluorescence information of cell particles.
[0015] According to a second aspect, one embodiment provides a blood analysis method, comprising:
[0016] The blood sample to be tested is stained with a fluorescent staining agent and hemolyzed with a hemolytic agent to prepare the test sample.
[0017] The cell particles in the sample are passed through the flow chamber one by one and exposed to light;
[0018] The device receives scattered light and fluorescence from cell particles under light irradiation and outputs scattered light information and fluorescence information. The scattered light information includes at least first angle scattered light information, which is used to reflect the size information of cell particles.
[0019] Reticulin particles are identified based on the first angle of scattered light and fluorescence information of cell particles.
[0020] According to a third aspect, one embodiment provides a blood analysis method for analyzing a sample, wherein the sample is generated from a blood sample to be tested after fluorescent staining and hemolysis reaction, the method comprising:
[0021] Data characterizing the first angle scattered light information and fluorescence information of cell particles are obtained. The first angle scattered light information and fluorescence information are based on the first angle scattered light and fluorescence generated when cell particles in the sample pass through the flow chamber one by one and are illuminated. The first angle scattered light information is used to reflect the size information of cell particles.
[0022] Based on the data, obtain the information about the web-woven red fabric.
[0023] According to a fourth aspect, one embodiment provides a computer-readable storage medium including a program that can be executed by a data processor to implement the above-described method.
[0024] According to a fifth aspect, one embodiment provides a blood analyzer, comprising:
[0025] Memory, used to store programs;
[0026] A data processor is used to implement the above method by executing a program stored in the memory.
[0027] In this embodiment of the invention, a white blood cell measurement channel is used to detect blood samples after hemolysis. Reticulocytes are identified using data from the blood shadow region, thus eliminating the need to design a separate optical detection channel in the blood analyzer to distinguish between reticulocytes and platelets, as well as to achieve more precise classification and counting of reticulocytes. Attached Figure Description
[0028] Figure 1Scatter plot of the red channel (RET channel) of Mindray BC-6800;
[0029] Figure 2 This is a schematic diagram of the structure of relevant parts of a blood analyzer in one embodiment;
[0030] Figure 3a This is a scatter plot of side-scattered light and fluorescence.
[0031] Figure 3b Forward scattered light-fluorescence scatter plot;
[0032] Figure 3c This is a magnified view of the blood-shadow area;
[0033] Figure 3d A schematic diagram illustrating the identification of nucleated erythrocytes while recognizing reticulin particles using a forward-scattered light-fluorescence scatter plot;
[0034] Figure 4a This is a flowchart illustrating the identification of reticulated red particles in one embodiment;
[0035] Figure 4b A flowchart illustrating the identification of large platelets and reticulocytes in one embodiment;
[0036] Figure 5 This is a schematic diagram of reticulocyte partitioning in one embodiment;
[0037] Figure 6 This is a histogram of platelet volume distribution in one embodiment;
[0038] Figures 7a-7d This is a comparison chart of platelet count information obtained using the method of this invention and the BC-6800 blood cell analyzer;
[0039] Figure 7e-7h This is a comparison chart of reticulocyte count information obtained using the scheme of this invention and the BC-6800 blood cell analyzer. Detailed Implementation
[0040] The present invention will now be described in further detail with reference to specific embodiments and accompanying drawings. Similar elements in different embodiments are referred to by associated similar element reference numerals. In the following embodiments, many details are described to facilitate a better understanding of this application. However, those skilled in the art will readily recognize that some features may be omitted in different situations, or may be replaced by other elements, materials, or methods. In some cases, certain operations related to this application are not shown or described in the specification. This is to avoid obscuring the core parts of this application with excessive description. For those skilled in the art, detailed description of these related operations is not necessary; they can fully understand the related operations based on the description in the specification and general technical knowledge in the art.
[0041] Furthermore, the features, operations, or characteristics described in the specification can be combined in any suitable manner to form various embodiments. At the same time, the steps or actions in the method description can be rearranged or adjusted in a manner obvious to those skilled in the art. Therefore, the various orders in the specification and drawings are only for the clear description of a particular embodiment and do not imply a necessary order, unless otherwise stated that a particular order must be followed.
[0042] The serial numbers assigned to components in this document, such as "first" and "second," are used only to distinguish the described objects and have no sequential or technical meaning. The terms "connection" and "linkage" used in this application, unless otherwise specified, include both direct and indirect connections (linkages).
[0043] In blood cell analyzers, although both white blood cell differential and reticulocyte detection utilize flow cytometry, they cannot share the same measurement channel. This is because the white blood cell measurement channel incorporates a hemolysis process to minimize interference from red blood cells. This process breaks down red blood cells into smaller fragments, preventing interference with white blood cell measurements. However, when detecting reticulocytes, theoretically, damage to reticulocytes is undesirable. Since hemolysins also lyse reticulocytes, existing flow cytometry-based reticulocyte measurement channels do not include a hemolysis process.
[0044] The contribution of this invention lies in discovering a scheme for detecting reticulocytes and / or platelets using a white blood cell measurement channel. This scheme can detect the number of platelets or other information, as well as the number of reticulocytes or other information, such as more precise classification and counting of reticulocytes. A key aspect of this invention is the discovery of a new use for blood shadow region data.
[0045] Please refer to Figure 2 , Figure 2 A schematic diagram of the structure of a blood cell analyzer according to a specific embodiment of the present invention is shown, including a sample preparation component, a measurement component 22, a data processor 25, and a display 26.
[0046] The sample preparation components include a sample dispensing device (not shown in the figure) and a reaction chamber 21. The sample dispensing device can be a sampling needle or a sampling valve. The sampling needle or sampling valve dispenses the aspirated blood sample or reagent into the reaction chamber 21 through a suction and discharge action. The sample and reagent can use their own separate sampling needles or sampling valves, or they can share a common sampling needle or sampling valve. The sample dispensing device may also include a sampling needle and a hydraulic line. The sampling needle is used to dispense the aspirated blood sample into the reaction chamber 21 through a suction and discharge action, and the hydraulic line is used to inject reagents into the reaction chamber 21 under positive or negative pressure. In this embodiment of the invention, the reagents include at least a fluorescent staining agent and a hemolytic agent. The reaction chamber 21 provides a mixing and incubation site for the blood sample, fluorescent staining agent, and hemolytic agent. When mixing the sample with the fluorescent staining agent and hemolytic agent, both or all three can be added simultaneously or sequentially. After mixing, under the action of the hemolytic agent, the red blood cells in the blood sample lyse, while the cells containing nucleic acids are stained by the fluorescent staining agent. The blood sample to be tested, along with fluorescent staining agent and hemolytic agent, is mixed and incubated to obtain the test sample.
[0047] The measuring component 22 includes a light source 22a, a flow chamber 22c, and photodetectors 22f, 22k, and 22g. The flow chamber 22c provides an area for cell particles in the sample to pass through and be illuminated one by one. Normally, the flow chamber 22c and the reaction cell 21 are connected by a conduit 27. After the sample is prepared, it reaches the inlet of the flow chamber 22c through the conduit 27, and then, under the influence of the sheath fluid, the cell particles in the sample pass through the flow chamber 22c one by one. The light emitted by the light source 22a is focused into the optical detection area of the flow chamber 22c by the collimating lens 22b. When cell particles flow through the optical detection area of the flow chamber 22c, the light beam illuminates the cell particles. Different types of cells emit different scattered light, and cells stained with fluorescent dyes also emit fluorescence. The photodetector collects light and fluorescence at two scattering angles. The first angle of scattering is light with a small angle to the optical axis, for example, light with an angle of 1-6° to the optical axis. The second angle of scattering is light with a larger angle to the optical axis, for example, light with an angle of 1-6° to the direction perpendicular to the optical axis. The first angle of scattering signal reflects the size of the cell particles, and the second angle of scattering signal reflects the complexity of the cell particles. Typically, the first angle of scattering is forward scattering, and the second angle of scattering is side scattering. Forward scattering refers to scattering collected in the direction of direct beam incidence (i.e., along the optical axis), and side scattering refers to scattering collected in the direction perpendicular to the optical axis. It should be understood that in other embodiments, those skilled in the art can set the first and second angles to other angle ranges as needed, as long as they reflect the size and complexity of the cell, respectively. In embodiments of the present invention, only the first angle of scattering signal and the fluorescence signal may be detected, or only the first angle of scattering signal may be detected. The light detection devices 22f, 22k, and 22g can be, for example, photoelectric sensors, which sense the intensity of light and convert the light signal into an electrical signal for output. The output electrical signal is amplified by amplifier 23 and then input to data processor 25.
[0048] In such Figure 2In the illustrated embodiment, forward-scattered light emitted by the cells is incident on a photodetector 22f after passing through a converging lens 22d and a microplate 22e. The photodetector 22f senses the light intensity and converts the optical signal into an electrical signal, which is then output as a forward-scattered light signal. Side-scattered light and side fluorescence emitted by the cells are split into two paths, side-scattered light and fluorescence, by a beam splitter 22h. The side-scattered light is incident on a photodetector 22g, which senses the light intensity and converts the optical signal into an electrical signal, which is then output as a side-scattered light signal. Fluorescence is incident on a photodetector 22k after passing through a converging lens 22i and a filter 22j. The photodetector 22k senses the fluorescence intensity and converts the optical signal into an electrical signal, which is then output as a fluorescence signal. The forward-scattered light signal, fluorescence signal, and side-scattered light signal are amplified by amplifiers 23a, 23b, and 23c, respectively, and then transmitted to a data processor 25.
[0049] The data processor 25 is used to perform calculations on the data to obtain the required results. For example, it can generate a two-dimensional scatter plot or a three-dimensional scatter plot based on various light signals from collected cell particles, and perform white blood cell analysis or other analyses on the scatter plot using a gating method. The data processor 25 can also visualize intermediate or final calculation results and then display them on the display 27.
[0050] In this embodiment of the invention, the data processor 25 identifies large platelets and / or reticulocytes based on the first angle scattered light signal and fluorescence signal of cell particles, or identifies large platelets and / or reticulocytes based on the first angle scattered light signal of cell particles, and then obtains large platelet information and / or reticulocyte information.
[0051] During the research, the inventors used leukocyte channels to detect forward scattered light signals (FSC), side scattered light signals (SSC), and fluorescence signals (FL) of cell particles, generating side scattered light-fluorescence scatter plots and forward scattered light-fluorescence scatter plots, such as... Figure 3a The image shows a scatter plot of side-scattered light and fluorescence. Figure 3b The image shows a scatter plot of forward-scattered light and fluorescence. Figure 3a and 3b In the scatter plot, the cell particles can be basically divided into two large particle regions: the white blood cell regions 31a and 31b with relatively high fluorescence signals, and the blood shadow regions 32a and 32b with relatively low fluorescence signals. The blood shadow regions are also considered non-white blood cell regions, consisting of the residue of red blood cells and platelets after hemolysis, and are commonly referred to as blood shadows. Data from blood shadow regions are often discarded in various analyses. The inventors discovered that in the forward-scattered light-fluorescence scatter plot, the blood shadow region 32b exhibits a special shape. Magnifying the blood shadow region 32b... Figure 3cIn the blood shadow region 32b, two branches are observed: a first branch 33 extending along the direction of forward scattering light and a second branch 34 extending along the direction of fluorescence. After theoretical analysis and experiments, the inventors believe that these two branches can be used to distinguish between large platelets and reticulocytes.
[0052] Existing research suggests that although the original volume of red blood cells is larger than that of platelets, after hemolysis with a hemolytic agent, red blood cells are broken down into very small fragments. For small platelets (e.g., those less than 10 fL), their volume is further reduced after treatment with the hemolytic agent due to their already small size. These small particles are difficult to distinguish accurately because the detection limit of the system is limited, and small platelets and red blood cell fragments are similar in size.
[0053] Through research, the inventors have realized that after blood is hemolyzed with a hemolytic agent, mature red blood cells dissolve into smaller fragments, which are difficult to identify due to their small size. However, reticulocytes contain basophilic punctate or even reticulated granules in their cytoplasm, which are difficult to dissolve. Therefore, the volume of hemolyzed reticulocytes will be slightly larger than that of hemolyzed mature red blood cells. Furthermore, because these granules contain nucleic acid, their fluorescence information will be greater than that of platelets after staining, and the more basophilic granules there are, the stronger the fluorescence. Moreover, the inventors believe that after hemolysis of blood samples, the volume of platelets decreases, but their relative size remains almost unchanged. That is, platelets that were originally large remain relatively large after hemolysis, and these large platelets can be detected by flow cytometry in the hemolysis channel. Based on the above analysis, the first branch 33 extending along the direction of forward scattering light can be considered to be large platelets, while the second branch 34 extending along the direction of fluorescence is reticulocyte particles. These reticulocyte particles may be basophilic granules encased in cell membranes after treatment with a hemolytic agent, or they may be basophilic granules released after cell membrane disruption. Since these particles contain nucleic acid, their fluorescence information will be greater than that of ordinary mature red blood cells, and the more basophilic granules there are, the stronger the fluorescence. In this paper, reticulocyte particles refer to particles that characterize reticulocytes. The inventors have found that the number of these particles is correlated with the number of reticulocytes in the sample. The lower left corner of the blood shadow is a mixture of mature red blood cell fragments and small platelets.
[0054] Based on this conclusion, it is envisioned that a suitable region, such as a second region 35, is set on the first branch 33 by setting a gate, so that the particles in this region are large platelets. The second region 35 refers to the region in the blood shadow region where the fluorescence signal intensity is relatively small and the first angle scattered light signal intensity is relatively large. In practical operation, the position and size of the second region 35 can be set according to the region where large platelets should or may appear, as recognized by theory and / or by the experience of those skilled in the art. That is, in the second region 35, cell particles can be identified as large platelets, and along the forward scattered light FSC to the right, the stronger the forward scattered light signal, the larger the platelet volume. Similarly, on the second branch 34, a suitable region is set by a gate method, such as the first region 36, so that the particles in this region are reticulocytes. The first region 36 refers to the region in the blood shadow region where the fluorescence signal intensity is relatively large and the first angle scattered light signal intensity is relatively small. The position and size of the first region 36 can also be set according to the theory and / or the experience of those skilled in the art, which recognizes the region where reticulocytes should or may appear. That is, in the first region 36, cell particles can be identified as reticulocyte particles, and along the fluorescence FL upward, the stronger the fluorescence signal, the more basophilic particles in the reticulocyte, and the more immature the reticulocyte.
[0055] The following specific examples illustrate various applications.
[0056] This embodiment uses the analysis of forward scattered light and fluorescence signals of cell particles as an example to illustrate the processing flow for analyzing the blood sample being tested, as follows: Figure 4a As shown, it includes the following steps:
[0057] Step 100: Collect the blood sample to be tested. Quantitatively collect the blood sample to be tested using a sampling needle or sampling valve, and inject a certain amount of the blood sample into the reaction chamber.
[0058] Step 101: Perform a hemolytic reaction on the blood sample using a hemolytic agent. The hemolytic agent is added to the reaction chamber to mix with the blood sample. The hemolytic agent is a reagent that causes red blood cells in the blood to dissolve. Therefore, under the action of the hemolytic agent, the red blood cells are dissolved, their volume decreases, and they become cell fragments.
[0059] Step 102: The blood sample is stained with a fluorescent staining agent. The fluorescent staining agent is added to the reaction chamber to mix with the blood sample. The fluorescent staining agent is a reagent used to stain nucleic acids; white blood cells contain nucleic acids and are therefore stained.
[0060] In another embodiment, the hemolytic agent and the fluorescent staining agent may be added to the reaction cell 21 simultaneously. In addition, other types of reagents may be added as needed for detection.
[0061] Step 103: The blood sample to be tested, the hemolysin, and the fluorescent staining agent added to the reaction cell 21 are mixed and incubated for a certain period of time to prepare the test sample.
[0062] The fluorescent staining agent used in this paper can be a conventional dye used for detecting leukocytes or nucleated red blood cells, such as the dye mentioned in Chinese patent application CN200910177186.7 or the dye mentioned in Chinese patent application CN200910238927.8. The hemolytic agent can be a conventional hemolytic agent; for example, the surfactants mentioned in these two patents can be formulated as hemolytic agents. Step 104: The sample is detected using flow cytometry. Through liquid path control, a certain amount of sample in the reaction cell flows to the flow chamber, where it mixes with the sheath fluid at the inlet. Cell particles in the sample pass through the light detection area of the flow chamber one by one under the influence of the sheath fluid. A beam of light emitted from the light source illuminates the light detection area, and the cell particles scatter the light. Different types of cell particles scatter different amounts of light. Simultaneously, because the cell particles are stained, when light illuminates the cell particles stained with the fluorescent staining agent, the cell particles produce fluorescence with a wavelength longer than the wavelength of the irradiated light. The more nucleic acid material present, the stronger the staining and the stronger the emitted fluorescence.
[0063] Step 105: Collect the scattered light and fluorescence of cell particles under light irradiation. The photodetector outputs the scattered light signal and fluorescence signal based on the intensity of the collected scattered light and fluorescence. In one embodiment, the following method can be used: Figure 2 The light collection system shown includes forward-scattered light signals and side-scattered light signals. Forward-scattered light is collected by a forward-scattered light collection device, and side-scattered light is collected by a side-scattered light collection device. The forward-scattered light signal is used to reflect the size information of cell particles, and the side-scattered light signal is used to reflect the complexity of cell particles.
[0064] Step 106: Obtain data characterizing the cell particles. Each cell particle generates three data points when it passes through the photodetector area: forward scattered light signal, side scattered light signal, and fluorescence signal. Each cell particle is characterized using three data points.
[0065] The data characterizing these cell particles can be temporarily stored in a buffer or in a memory. For example, the three data points of each cell particle can be stored as a three-dimensional data set. Each data set includes forward scattering information, side scattering information, and fluorescence information. Multiple data sets of cell particles can form a data matrix. The data processor reads the cell particle data from the buffer or memory for subsequent processing. Alternatively, this data characterizing the cell particles can be directly transmitted to the data processor. The data processor can perform particle identification based on at least two dimensions of the data set characterizing the cell particles. For example, in this embodiment, the data processor can identify reticulin particles based on forward scattering information and fluorescence information. For instance, the forward scattering information and fluorescence information are compared with corresponding preset standards, and particles falling within a predetermined range are identified as reticulin particles based on the comparison results. Another example is the scatter plot method used to identify particles.
[0066] In some embodiments, if only two-dimensional data is needed to identify particles, the light collection system may collect only two of the forward-scattered light information, side-scattered light information, and fluorescence information.
[0067] Step 108: Generate a scatter plot based on the data characterizing cell particles, for example, generating a forward-scattered light-fluorescence scatter plot based on forward-scattered light information, side-scattered light information, and fluorescence information, such as... Figure 3b As shown.
[0068] Step 113: Identify the particles in the first region 36 as reticulated red particles.
[0069] In a further embodiment, when further statistics and / or applications of the reticulated red particles are required, the following steps may also be performed.
[0070] Step 114: Obtain reticulocyte information based on the identified reticulocyte particles. The reticulocyte information includes at least one of the following: reticulocyte marker information, reticulocyte count information (RET), high-fluorescence reticulocyte count information, medium-fluorescence reticulocyte count information, low-fluorescence reticulocyte count information, immature reticulocyte count information, and the content of nucleic acid material within reticulocytes.
[0071] Reticulocyte count information includes the number of reticulocytes (RET#) and / or the reticulocyte percentage (RET%). The number of reticulocytes can be obtained by counting the number of particles in the first region. The reticulocyte percentage is the ratio of the number of reticulocytes to the number of red blood cells in the same test sample.
[0072] Within the first region 36, the stronger the fluorescence signal upwards along the fluorescence FL, the more nucleic acids and basophilic granules are present in the reticulocytes, indicating that the reticulocytes are less mature. The data processor can obtain high-fluorescence reticulocyte count information, medium-fluorescence reticulocyte count information, and low-fluorescence reticulocyte count information based on the fluorescence signal intensity distribution of particles in the first region 36. For example, within the first region 36, a third region 37, a fourth region 38, and a fifth region 39 can also be defined using a gating method, such as... Figure 5 As shown.
[0073] Region 37 is for high-fluorescence reticulocytes, and its location is determined based on theoretical and / or experience of those skilled in the art as areas where immature reticulocytes should or may be present. High-fluorescence reticulocyte count information includes the high fluorescent ratio (HFR) and / or the high fluorescent reticulocyte count value (HFR#). The high fluorescent reticulocyte count value (HFR#) is obtained by statistically analyzing the number of particles within Region 37. The high fluorescent reticulocyte ratio (HFR) is the ratio of the number of high fluorescent reticulocytes to the number of reticulocytes in the same assay sample.
[0074] Region 38 is for medium-fluorescent reticulocytes, and its location is determined based on theoretical and / or experience of those skilled in the art, as areas where immature reticulocytes should or may be present. Medium-fluorescent reticulocyte count information includes the count value of medium-fluorescent reticulocytes and / or the middle-fluorescent ratio (MFR). The MFR# of medium-fluorescent reticulocytes is obtained by statistically analyzing the number of particles within region 38. The MFR is the ratio of the number of medium-fluorescent reticulocytes to the number of reticulocytes in the same assay sample.
[0075] Region 39 is for low-fluorescence reticulocytes. Its location is determined based on the theory and / or the experience of those skilled in the art, as to the area where mature reticulocytes should or may be present. The low-fluorescence reticulocyte count information includes the count value of low-fluorescence reticulocytes and / or the low-fluorescence reticulocyte ratio (LFR). The count value of low-fluorescence reticulocytes, LFR#, can be obtained by statistically analyzing the number of particles in Region 39. The low-fluorescence reticulocyte ratio, LFR, is the ratio of the number of low-fluorescence reticulocytes to the number of reticulocytes in the same test sample.
[0076] Immature reticulocyte count information includes the immature reticulocyte count value and / or the immature reticulocyte fraction (IRF). The immature reticulocyte fraction is equal to the sum of the MFR and HFR. The immature reticulocyte count value IRF# can be calculated as IRF# = RET# * IRF. Alternatively, the immature reticulocyte count value IRF# can be obtained based on the number of high-fluorescence and medium-fluorescence reticulocytes. The immature reticulocyte fraction is the ratio of the number of immature reticulocytes to the number of reticulocytes in the same test sample.
[0077] Furthermore, the fluorescence signal intensity of reticulocytes can characterize the nucleic acid content of reticulocytes; the more nucleic acid content, the stronger the fluorescence. Therefore, by summing the fluorescence signals of reticulocytes, the nucleic acid content within reticulocytes can be calculated. The formula for calculating the nucleic acid content is as follows:
[0078]
[0079] Where, N RET FL is a measure of the amount of nucleic acid content in reticulocytes. RET-i The fluorescence signal intensity of the i-th reticulocyte. Nucleic acid content can potentially be used to monitor the maturation process of erythrocytes. Higher nucleic acid content indicates more immature reticulocytes detected in the blood, or more immature reticulocytes, closer to late erythroblasts. To some extent, nucleic acid content can reflect the severity of blood disorders.
[0080] Reticulocyte marker information refers to the detection of reticulocyte particles, or it can also refer to the detection of reticulocytes at a certain maturity level. Reticulocyte marker information is a qualitative indicator; for example, when reticulocyte particles or reticulocytes at a certain maturity level are detected, the reticulocyte marker information is set to 1; when no reticulocyte particles of the predetermined type are detected, the reticulocyte marker information is set to 0.
[0081] In some embodiments, alarms can also be triggered based on reticulocyte information. For example, an alarm can be triggered based on reticulocyte marker information, i.e., an alarm is triggered when the reticulocyte marker information is set to 1. Alternatively, an alarm can be triggered based on reticulocyte count information, i.e., an alarm is triggered when the reticulocyte count exceeds a set threshold. Alternatively, an alarm can be triggered based on the high-fluorescence reticulocyte count information or the nucleic acid content within the reticulocytes.
[0082] In another embodiment, the data processor can also identify large platelets based on forward-scattered light and fluorescence scatter plots, as follows: Figure 4b As shown, in Figure 4aIn addition to this, the following steps are also included:
[0083] Step 109: Identify the blood shadow region 32b on the scatter plot. The blood shadow region is usually located in the lower left corner of the scatter plot. A gating method can be used empirically to set the blood shadow region on the scatter plot. In this approach, the blood shadow region is pre-defined and fixed. Alternatively, the blood shadow region can be determined without pre-setting. For example, it can be determined based on the white blood cell distribution area. The white blood cell distribution area can be a pre-defined area or an area determined based on the actual white blood cell distribution detected. In this approach, the data processor first reads the white blood cell distribution area and then uses it to determine the blood shadow region. For example, the center of the white blood cell distribution area is shifted to the lower left by a predetermined distance to obtain the center of the blood shadow region. Then, a circle or ellipse is drawn based on the center of the blood shadow region and a predetermined radius to obtain the blood shadow region.
[0084] Step 110: Obtain the second region 35 and the first region 36 based on the blood shadow region. Based on theory and experience, a specific region of the first branch of the blood shadow region can be designated as the second region 35, and a specific region of the second branch can be designated as the first region 36, such as... Figure 3c As shown, the second region 35 and the first region 36 are located within the blood shadow region.
[0085] Step 111: Identify the particles in the second region 35 as large platelets.
[0086] Step 112: Obtain platelet information based on the identified large platelets. The platelet information includes at least one of the following: platelet size, platelet volume distribution, and platelet count.
[0087] The platelet count information includes the number of large platelets and / or the platelet ratio. The number of large platelets can be obtained by counting the number of particles in the first region. The platelet ratio is the ratio of the number of large platelets to the total number of platelets in the same sample.
[0088] The size of large platelets can be calculated at least based on the forward scattered light signal from the large platelets, for example, by any of the following methods:
[0089] 1. If forward scattering (FSC) and lateral scattering (SSC) information of particles are detected simultaneously, the size of large platelets can be calculated using Mie scattering theory. For details, please refer to the literature "Forward Scattering of Red Blood Cells", Laser Biology, Vol. 5, No. 2, June 1996.
[0090] 2. Only forward astigmatism information can be detected, and the size of large platelets can be calculated using formula (1), where k is a constant, Vol is the size of large platelets, and FSC is the forward scattered light of the particle.
[0091] Vol=k*FSC------(1)
[0092] Alternatively, the volume of large platelets can be calculated using formula (2), where k and b are constants.
[0093] Vol=k*exp(b*FSC)--------(2)
[0094] 3. Only anterior astigmatism information can be detected, and the volume of large platelets can be calculated using formula (3), where μ and σ are constants.
[0095] Vol=[1 / (FSC*σ(2π) 1 / 2 )]exp(-(lnFSC-μ) 2 / 2σ 2 )-----(3)
[0096] Based on the size of large platelets, their volume distribution can be obtained, for example, by generating a histogram of large platelet volume distribution. Figure 6 As shown. In some embodiments, platelet volume distribution information can also be obtained by segmenting statistics along the forward scattering optical axis.
[0097] To verify the effectiveness of this solution, the results obtained using the embodiments of this invention will be compared with the results obtained using the BC-6800 blood cell analyzer. Figures 7a-7h As shown, Figures 7a-7d The correlation between platelet count information obtained using the embodiments of the present invention and platelet count information obtained using the BC-6800 blood cell analyzer is demonstrated. Figure 7e-7h The correlation between reticulocyte count information obtained using the embodiments of the present invention and reticulocyte count information obtained using the BC-6800 blood cell analyzer is demonstrated.
[0098] Example
[0099] Blood samples were analyzed using the white blood cell detection channel of the BC-6800 hematology analyzer (hereinafter referred to as the BC-6800 hematology analyzer) manufactured by Shenzhen Mindray Bio-Medical Electronics Co., Ltd. The reticulocyte channel of the BC-6800 hematology analyzer employs flow cytometry technology, enabling the detection of reticulocyte counts using forward scattering light and fluorescence. The scatter plot is shown below. Figure 1 As shown.
[0100] In addition, from Figure 1 It is evident that forward-scattered light and fluorescence signals can be used to identify platelets and obtain the total number of platelets. Based on the forward-scattered and side-scattered light signals of platelet particles, the volume of each platelet is calculated using Mie scattering theory (Zhang Wei, Lu Yuan, Du Shiming, et al., Analysis of Mie Scattering Characteristics of Spherical Particles, Optical Technology, November 2010: Vol. 36, No. 6: 936-939.), thus obtaining the number of platelets with different volumes.
[0101] Please refer to Figures 7a-7d A comparative experiment selected 82 samples, including 15 samples of red blood cell fragments confirmed by manual microscopic examination, 5 samples of small red blood cells, 5 samples of large platelets, and 57 normal samples. Using the scheme described in this invention, the samples were detected in the white blood cell detection channel of the Mindray BC-6800 blood cell analyzer. The forward scattered light signal of 35 particles in the second region was obtained, yielding the volume distribution data of large platelets. Specifically, the forward scattered light signal FSC can be converted into the volume of each particle in this region using formula (1), thereby obtaining the volume distribution data of large platelets. For example... Figure 6 As shown. The volume distribution data can be in digital or graphical form, such as a volume histogram. Further, based on this large platelet volume distribution data, platelet counts of volumes greater than 10 fL, 12 fL, 15 fL, and 20 fL were measured. The same blood samples were tested in the reticulum channel of a Mindray BC-6800 blood cell analyzer. The platelet counts of different volumes were calculated using the aforementioned method. In the graph, the horizontal axis represents the platelet counts of volumes greater than 10 fL, 12 fL, 15 fL, and 20 fL measured using the BC-6800 blood cell analyzer (referred to as BC-6800 in the graph), and the vertical axis represents the platelet counts of volumes greater than 10 fL, 12 fL, 15 fL, and 20 fL measured using the method of this invention (referred to as this invention in the graph). As shown in the graph, the squares of the correlation coefficients of the two detection methods reached 0.94, 0.945, 0.935, and 0.924, respectively.
[0102] Please refer to Figure 7e-7hA comparative experiment was conducted with 88 samples. Of these, 25 samples showed RET% < 0.5%, 19 samples showed RET% < 3% (0.5 ≤ RET% < 3%), and 44 samples showed RET% > 3%. The assay described in this invention and the BC-6800 blood cell analyzer were used for detection. The reticulocyte measurement channel of the BC-6800 blood cell analyzer can detect the percentage and count of reticulocytes (RET% / RET#), the percentage of low fluorescent reticulocytes (LFR), the percentage of middle fluorescent reticulocytes (MFR), the percentage of high fluorescent reticulocytes (HFR), and the proportion of immature reticulocytes (IRF, the sum of MFR and HFR). By conversion, the reticulocyte count values can be obtained as follows: LFR# = RET# * LFR (low fluorescence intensity), MFR# = RET# * MFR (medium fluorescence intensity), HFR# = RET# * HFR (high fluorescence intensity), and IRF# = RET# * IRF (immature reticulocyte count). Furthermore, by summing the fluorescence signal intensities of reticulocytes detected using the BC-6800 blood cell analyzer, the nucleic acid content (N) of reticulocytes can be characterized. RET In the figure, the horizontal axis represents the statistical information of RET#, IRF#, HFR#, and fluorescence sum measured using the BC-6800 blood cell analyzer (hereinafter referred to as BC-6800 in the figure), and the vertical axis represents the statistical information of RET#, IRF#, HFR#, and fluorescence sum measured using the method of this invention (hereinafter referred to as this invention in the figure). As shown in the figure, the squared correlation coefficients of the two detection methods reached 0.847, 0.746, 0.737, and 0.864, respectively. The comparison results show that the number of particles in a specific region can effectively characterize reticulin information in blood.
[0103] In other embodiments, the present invention can also be performed on the nucleated red blood cell detection channel of the BC-6800 blood cell analyzer, and similarly to the white blood cell channel, to obtain reticulocyte information and platelet count.
[0104] In a further improved embodiment, an alarm can also be triggered based on the platelet count information obtained from the above embodiments. For example, when the platelet count exceeds a set threshold, an alarm can be triggered by sound, text or highlighting on the display screen, or text or highlighting on the printed report.
[0105] Those skilled in the art should understand that, in other specific embodiments, only two data points—forward scattered light signal and fluorescence signal—may be collected, meaning each cell particle is characterized using two data points. The first, second, third, fourth, and fifth regions can be preset based on experience or determined from pre-defined regions. For example, once the blood shadow region is determined, a specific region at a first distance and orientation from the center of the blood shadow region can be determined as the first region distinguishing large platelets; a specific region at a second distance and orientation from the center of the blood shadow region can be determined as the second region distinguishing reticulocytes; the upper third of the second region can be determined as the third region distinguishing highly fluorescent reticulocytes; the middle third of the second region can be determined as the fourth region distinguishing moderately fluorescent reticulocytes; and the lower third of the second region can be determined as the fifth region distinguishing low-fluorescence reticulocytes. In some specific embodiments, a scatter plot can be displayed on a screen, allowing the user to manually determine each region based on experience. In this embodiment, the blood shadow region may not be specified, i.e., step 109 is not performed, and the first, second, third, fourth, and fifth regions are directly specified on the scatter plot.
[0106] In some embodiments, a three-dimensional scatter plot can be generated based on forward-scattered light information, side-scattered light information, and fluorescence information. Then, reticulin particles and / or large platelets are identified based on the distribution of particles in the forward-scattered light dimension and fluorescence dimension of the scatter plot.
[0107] This embodiment primarily describes the use of gating on a scatter plot to distinguish between reticulocytes and platelets. In some embodiments, a comparison with thresholds can also be used to identify which particles belong to reticulocytes and which belong to platelets. For example, a first and second threshold range can be set for forward scattered light, and a third and fourth threshold range can be set for fluorescence. Particles whose forward scattered light falls within the first threshold range and whose fluorescence falls within the third threshold range are identified as platelets, while particles whose forward scattered light falls within the second threshold range and whose fluorescence falls within the fourth threshold range are identified as reticulocytes. In this embodiment, it is not necessary to generate a scatter plot.
[0108] In some cases, only the identification and analysis of large platelets or only the identification and analysis of reticulocytes may be performed.
[0109] Through in-depth research, the applicant discovered that after hemolysis of red blood cells in blood samples, reticulocytes form reticulocyte particles, which can be at least partially distinguished from red blood cell fragments on a forward scattering-fluorescence scatter plot, yielding reticulocyte particle information, including the number of reticulocyte particles, which is correlated with the reticulocyte information in the sample.
[0110] Since the embodiments of the present invention employ a white blood cell measurement channel that requires the dissolution of red blood cells, in some embodiments, white blood cell analysis can be performed using the same measurement data, including white blood cell classification and counting, such as performing a four-part differential white blood cell count (e.g., Figure 3a As shown, white blood cells are classified into four subsets: lymphocytes, monocytes, neutrophils, and eosinophils; basophil classification; and nucleated red blood cell classification. A scatter plot can be generated based on any two signals from forward scatter, side scatter, and fluorescence. White blood cells are then classified and counted using a gating method on the scatter plot. Those skilled in the art will understand that other detection methods that require the dissolution of red blood cell measurement channels, such as nucleated red blood cell channels, can also utilize the method of this invention to identify nucleated red blood cells (e.g., reticulocytes) simultaneously with reticulocyte particles. Figure 3d (As shown).
[0111] In another embodiment, the detection of reticulocytes can be performed using a hemolytic agent with strong hemolytic ability against red blood cells, combined with a fluorescent dye. The hemolytic agent can be at least one selected from alkyl glycosides, triterpenoid saponins, and steroidal saponins. Such hemolytic agents can better reduce the interference of fragments from lysed red blood cells on large platelets and reticulocyte particles.
[0112] A specific hemolytic agent may be a glycoside compound having the general formula I:
[0113] R-(CH2) n -CH3(I)
[0114] R is selected from the group consisting of monosaccharides, deoxymonosaccharides, and polysaccharides, and n is an integer from 5 to 17.
[0115] The aforementioned glycoside compounds can rapidly lyse red blood cells. Glycoside compounds are formed by the dehydration of the hemiacetal hydroxyl group of a sugar (or polysaccharide) and the hydroxyl group of an alkanol. The glycoside compound in the hemolytic agent of this invention can be a single compound or a mixture of two or more glycoside compounds conforming to the above general formula.
[0116] In general formula (I), there are no particular restrictions on monosaccharides, and commonly used ones can be selected from pentoses, methylpentoses, and hexoses, but are not limited to these. Examples of pentoses include arabinose, xylose, ribose, and lysolose. Examples of methylpentoses include fructose, rhamnose, and cinolose. Examples of hexoses include glucose, mannose, fructose, galactose, and sorbose. There are also no particular restrictions on deoxymonosaccharides, such as deoxyribose and deoxyglucose, but are not limited to these. Examples of polysaccharides include maltose and sucrose, but are not limited to these. n is preferably an integer from 6 to 14, more preferably an integer from 7 to 11.
[0117] The glycoside compound of general formula I may specifically be octyl glucoside, nonyl glucoside, decanyl glucoside, dodecyl maltoside, tetradecyl maltoside, dodecyl glucoside, preferably octyl glucoside, nonyl glucoside, decanyl glucoside, dodecyl maltoside, more preferably decanyl glucoside, dodecyl maltoside.
[0118] The concentration of the glycoside compound of general formula I in the hemolytic agent of this embodiment varies depending on the properties of the selected glycoside, reaction time, reaction temperature, and the amount of other components used. The typical amount used is in the range of 0.025 g / L to 10 g / L, preferably 0.1 g / L to 5.0 g / L.
[0119] The hemolytic agent in this first embodiment preferably further comprises a nonionic surfactant having general formula II:
[0120] R1-R2-(CH2CH2O) m -H (II)
[0121] Wherein, R1 is a C8-C23 alkyl group, and R2 is an -O-, Or -COO-, where m is an integer from 10 to 50; and
[0122] Optionally, at least one organic acid or a salt thereof, wherein the organic acid or salt thereof is selected from the group consisting of organic acids having at least one carboxyl or sulfonic acid group and their alkali metal salts.
[0123] Nonionic surfactants of formula II can bind to the cell membrane of leukocytes to a certain extent, thus protecting the cell membranes of leukocytes and platelets from the influence of the aforementioned glycoside compounds and maintaining or essentially maintaining their cell morphology.
[0124] According to a preferred embodiment, in the nonionic surfactant of general formula II, R1 is a C8-C18 straight-chain alkyl group. Specifically, the C8-C18 straight-chain alkyl group can be octyl, decanyl, lauryl, tetradecyl, hexadecyl, or stearyl. More preferably, R1 is a C12-C16 straight-chain alkyl group, specifically lauryl, tetradecyl, or hexadecyl. R2 is preferably -O-. m is 10-50, preferably 15-30.
[0125] Specific examples of the nonionic surfactant of general formula II may be hexadecyl alcohol polyoxyethylene (15) ether, dodecyl alcohol polyoxyethylene (21) ether, hexadecyl alcohol polyoxyethylene (23) ether, hexadecyl alcohol polyoxyethylene (25) ether, hexadecyl alcohol polyoxyethylene (30) ether, but are not limited thereto.
[0126] There is no particular limitation on the concentration of the nonionic surfactant of formula II, but it can be 0.03 to 1.5 g / L, preferably 0.05 to 1.0 g / L.
[0127] In this embodiment, the nonionic surfactant can be used as a single substance or as a mixture of two or more. The concentration of the nonionic surfactant in the hemolytic agent varies depending on the type of nonionic surfactant used. Generally, nonionic surfactants with longer alkyl chains and a higher number of repeating units in the polyoxyethylene moiety have relatively lower concentrations.
[0128] In this embodiment, compounds of general formula I and general formula II are used in combination to achieve rapid and deep lysis of red blood cells, and to protect platelet cell membranes in order to effectively detect platelets.
[0129] The ratio of compounds of general formula I and general formula II varies depending on the compounds selected. However, generally speaking, the ratio of compounds of general formula I to general formula II is 1:100 to 1:3, preferably 1:25 to 1:5, and more preferably 1:10 to 1:5.
[0130] According to a preferred embodiment of this invention, the hemolytic agent may further comprise at least one organic acid or a salt thereof to improve the discrimination of leukocyte side-scattered light. The organic acid is preferably a mono-, di-, or tricarboxylic acid of C1-6 alkyl groups, either unsubstituted or substituted with hydroxyl or amino groups; a sulfonic acid of C1-6 alkyl groups, either unsubstituted or substituted with hydroxyl or amino groups; a C6-10 aryl-C1-6 alkyl acid; a C6-10 aryldi(C1-6 alkyl acid); and a C6-10 arylsulfonic acid.
[0131] Specific examples of the organic acids and their salts may include formic acid, acetic acid, benzoic acid, citric acid (3-hydroxy-1,3,5-pentanetricoic acid), malic acid (2-hydroxybutyric acid), phthalic acid, benzenesulfonic acid, α-naphthalenesulfonic acid, taurine, and their alkali metal salts, such as sodium salts and potassium salts, but are not limited thereto.
[0132] The concentration of the organic acid or organic acid salt in the hemolysin is from 0.05 g / L to 2 g / L, preferably from 0.1 g / L to 0.5 g / L.
[0133] The hemolytic agent of this embodiment may further include conventional additives. These additives may be selectively added as needed, such as (but not limited to) buffers, metal chelating agents, osmotic pressure regulators, preservatives, etc. These reagents are all commonly used in the art, as long as they do not interfere with the function of the above-mentioned components in the hemolytic agent of this embodiment. Buffers may be, for example, selected from phosphoric acid and its salts, citric acid and its salts, TRIS, etc., and are usually a buffer system consisting of two or more of them. Metal chelating agents are used as anticoagulants, such as sodium EDTA. Osmotic pressure regulators are usually inorganic salts, such as sodium chloride, sodium sulfate, potassium sulfate, sodium borate, etc. Preservatives include, for example, isothiazolinone, sodium azide, imidazolidinyl urea.
[0134] There are no particular restrictions on the mixing ratio of the hemolytic agent to the blood sample. For example, the volume ratio of blood sample to hemolytic agent can be 1:40 to 1:60. The hemolysis reaction is carried out at a temperature such as 40 to 60°C for 15 to 100 seconds, preferably 40 to 80 seconds. The reaction temperature and time can be adjusted according to specific conditions.
[0135] The components of a specific reagent are as follows:
[0136]
[0137] Fluorescent dye structural formula:
[0138]
[0139] The contribution of this invention to the prior art lies in the discovery of a scheme for detecting reticulocytes and / or large platelets using measurement channels that require hemolysis of red blood cells, such as white blood cell measurement channels. This scheme can detect the number of large platelets or other information, as well as the number of reticulocytes or other information, such as more precise classification and counting of reticulocytes. This allows white blood cell classification and counting, reticulocyte information, and large platelet information to be obtained from scattered light and fluorescence information collected in a single test. Therefore, the technical solution of this invention has the following effects:
[0140] First, it saves measurement channels, which is conducive to the miniaturization of blood analyzers.
[0141] Secondly, it reduces testing costs. On the one hand, white blood cells, reticulocytes, and platelets can be identified based on the scattered light and fluorescence information collected in a single test, saving on the amount of testing reagents used. On the other hand, the reagents for detecting white blood cell classification and counting are much cheaper than those for refined detection of reticulocyte information. First, a large number of samples are tested using the method of this invention to identify suspicious samples, and then refined detection is performed on the suspicious samples as needed, thereby reducing the testing cost of large numbers of samples.
[0142] Third, it saves testing time by providing information on white blood cells, reticulocytes, and platelets in a single testing channel.
[0143] Those skilled in the art will understand that all or part of the steps of the various methods in the above embodiments can be implemented by a program instructing related hardware. This program can be stored in a computer-readable storage medium, which may include a read-only memory, random access memory, a disk, or an optical disk. For example, the program can be stored in the analyzer's memory. When sample testing is required, the processor executes the program in the memory to achieve the above steps. In particular, during the actual implementation of this invention, steps 107-114 and 206-211 in the above embodiments can be written as independent programs. These programs can be stored on a server, disk, optical disk, or flash drive. They can be downloaded and saved to the local analyzer's memory, or the local analyzer's system can be updated by downloading. When sample testing is required, the processor executes the program in the memory to achieve the functions of steps 107-114 and 206-211.
[0144] The above examples illustrate the present invention and are only intended to aid in understanding the invention, not to limit it. Those skilled in the art can make variations to the specific embodiments described above based on the spirit of the invention.
Claims
1. A blood analyzer, characterized in that it comprises: A sample preparation component is used to prepare a test sample. The sample preparation component includes at least a reaction chamber, which provides a place for mixing and incubating the blood sample to be tested, a fluorescent staining agent, and a hemolysin. The mixing and incubation causes the red blood cells in the blood sample to lyse and stains the cell particles in the sample. The flow chamber is used to provide a region for individual cell particles in the sample to pass through and receive light; The measuring component includes a light source and a light detection device. The light source is used to emit a light beam that illuminates the flow chamber. The light detection device is used to receive the scattered light and fluorescence of cell particles under light irradiation and output scattered light information and fluorescence information. The scattered light information includes at least first angle scattered light information, which is used to reflect the size information of cell particles. A data processor for classifying and / or counting white blood cells based on information about the scattered light from cellular particles; It is also used to generate a scatter plot based on the first angle scattered light information and fluorescence information of cell particles, and to identify reticulin particles from the blood shadow region of the scatter plot; or, it is also used to compare the first angle scattered light information and fluorescence information with corresponding preset standards respectively, and to identify particles falling into a predetermined range as reticulin particles according to the comparison results.
2. The blood analyzer as described in claim 1, characterized in that, The data processor identifies reticulated red particles from the blood shadow region of the scatter plot by: identifying particles in a first region of the scatter plot as reticulated red particles, wherein the first region refers to the region in the blood shadow region where the fluorescence signal intensity is relatively large and the first angle scattered light signal intensity is relatively small.
3. The blood analyzer as described in claim 1, characterized in that, The data processor also obtains reticulated red information based on the identified reticulated red particles.
4. The blood analyzer as described in claim 3, characterized in that, The reticulocyte information includes at least one of the following: reticulocyte marker information, reticulocyte count information, high-fluorescence reticulocyte count information, medium-fluorescence reticulocyte count information, low-fluorescence reticulocyte count information, immature reticulocyte count information, and reticulocyte nucleic acid content.
5. The blood analyzer as described in claim 4, characterized in that, The data processor acquires high-fluorescence reticulocyte count information, medium-fluorescence reticulocyte count information, and low-fluorescence reticulocyte count information based on the fluorescence signal intensity distribution of reticulocyte particles.
6. The blood analyzer as described in claim 4, characterized in that, The data processor obtains the nucleic acid content by summing the fluorescence signal intensity of the reticulated red particles.
7. The blood analyzer as described in any one of claims 3-6, characterized in that, The data processor also issues an alarm based on the network red information at least once.
8. The blood analyzer as described in any one of claims 1-6, characterized in that, The data processor also identifies large platelets based on the first angle of light scattering and fluorescence information of cell particles.
9. The blood analyzer as described in claim 8, characterized in that, The data processor identifies the particles in the second region of the scatter plot as large platelets. The second region refers to the area in the blood shadow region where the fluorescence signal intensity is relatively low and the first angle scattered light signal intensity is relatively high.
10. The blood analyzer as described in claim 8, characterized in that, The data processor also obtains platelet information based on the identified large platelets.
11. The blood analyzer as described in claim 10, characterized in that, Platelet information includes at least one of the following: platelet size, platelet volume distribution, and platelet count.
12. The blood analyzer as described in claim 11, characterized in that, The data processor calculates the volume of the large platelets based at least on the first angle of scattered light information from the large platelets.
13. The blood analyzer as described in claim 11, characterized in that, The data processor also generates alarms based on the platelet count information.
14. The blood analyzer as described in claim 1, characterized in that, The data processor determines the blood shadow region based on the distribution area of white blood cells.
15. A blood analysis method, characterized in that it includes: The blood sample to be tested is stained with a fluorescent staining agent and hemolyzed with a hemolytic agent to prepare the test sample. The cell particles in the sample are passed through the flow chamber one by one and exposed to light; The device receives scattered light and fluorescence from cell particles under light irradiation and outputs scattered light information and fluorescence information. The scattered light information includes at least first angle scattered light information, which is used to reflect the size information of cell particles. White blood cell classification and / or counting are performed based on the scattered light information from cell particles; A scatter plot is generated based on the first angle scattered light information and fluorescence information of cell particles, and reticulin particles are identified from the blood shadow region of the scatter plot; or, the first angle scattered light information and fluorescence information are compared with the corresponding preset standards respectively, and particles falling into the predetermined range are identified as reticulin particles according to the comparison results.
16. The method as described in claim 15, characterized in that, Identifying reticulated red particles from the blood shadow region of the scatter plot includes: identifying particles in a first region of the scatter plot as reticulated red particles, where the first region refers to the region in the blood shadow region where the fluorescence signal intensity is relatively high and the first angle scattered light signal intensity is relatively low.
17. The method as described in claim 15, characterized in that... Also includes: Reticulated red information is obtained based on the identified reticulated red particles.
18. The method as described in claim 17, characterized in that, The reticulocyte information includes at least one of the following: reticulocyte marker information, reticulocyte count information, high-fluorescence reticulocyte count information, medium-fluorescence reticulocyte count information, low-fluorescence reticulocyte count information, immature reticulocyte count information, and reticulocyte nucleic acid content.
19. The method as described in claim 18, characterized in that, Information on high-fluorescence reticulocyte counts, medium-fluorescence reticulocyte counts, and low-fluorescence reticulocyte counts was obtained based on the fluorescence signal intensity distribution of reticulocyte particles.
20. The method as described in claim 18, characterized in that, The content of nucleic acid substances is obtained by summing the fluorescence signal intensity of the reticulated red particles.
21. The method according to any one of claims 17-20, characterized in that, At the very least, an alarm should be triggered based on the information provided by the online influencer.
22. The method according to any one of claims 15-20, characterized in that... It also includes identifying large platelets based on the first angle scattered light information and fluorescence information of cell particles.
23. The method as described in claim 22, characterized in that, Identifying large platelets based on the first-angle scattered light and fluorescence information of cell particles includes: generating a scatter plot based on the first-angle scattered light and fluorescence information of cell particles, and identifying particles in the second region of the scatter plot as large platelets. The second region refers to the region in the blood shadow region where the fluorescence signal intensity is relatively small and the first-angle scattered light signal intensity is relatively large.
24. The method as described in claim 22, characterized in that... It also includes obtaining platelet information based on the identified large platelets.
25. The method as described in claim 24, characterized in that, Platelet information includes at least one of the following: platelet size, platelet volume distribution, and platelet count.
26. The method as described in claim 25, characterized in that, The volume of large platelets should be calculated based on at least the information of the first angle of light scattered by the large platelets.
27. The method as described in claim 25, characterized in that, An alarm will be triggered based on the platelet count.
28. The method as described in claim 15, characterized in that... It also includes determining the blood shadow region based on the distribution area of white blood cells.
29. A blood analysis method for analyzing a sample, wherein the sample is generated from a blood sample to be tested after fluorescent staining and hemolysis, characterized in that... The method includes: Data characterizing the first angle scattered light information and fluorescence information of cell particles are obtained. The first angle scattered light information and fluorescence information are based on the first angle scattered light and fluorescence generated when cell particles in the sample pass through the flow chamber one by one and are illuminated. The first angle scattered light information is used to reflect the size information of cell particles. White blood cell classification and / or counting are performed based on the scattered light information from cell particles; A scatter plot is generated based on the first angle scattered light information and fluorescence information of cell particles. Reticulin particles are identified from the blood shadow region of the scatter plot, and reticulin information is obtained based on the identified reticulin particles. Alternatively, the first angle scattered light information and fluorescence information are compared with corresponding preset standards. Based on the comparison results, particles falling within a predetermined range are identified as reticulin particles, and reticulin information is obtained based on the identified reticulin particles.
30. The method as described in claim 29, characterized in that, Reticulated red particles are identified from the blood shadow region of the scatter plot, and reticulated red information is obtained based on the identified reticulated red particles, including: The particle information in the first region of the scatter plot is obtained, and the particle information in the first region is used to represent the reticulin information in the blood. The first region refers to the region in the blood shadow region where the fluorescence signal intensity is large and the first angle scattered light signal intensity is small.
31. The method as described in claim 29, characterized in that... It also includes obtaining platelet information based on the first angle scattered light information and fluorescence information of cell particles.
32. The method as described in claim 31, characterized in that... The method includes obtaining platelet information based on the first angle scattered light information and fluorescence information of cell particles, including: obtaining particle information in a second region of the scatter plot of the first angle scattered light information and fluorescence information, and characterizing the particle information in the second region to represent platelet information in the blood. The second region refers to the region in the blood shadow region where the fluorescence signal is small and the first angle scattered light signal is large.
33. A computer-readable storage medium, characterized in that, Includes a program that can be executed by a data processor to implement the method as described in any one of claims 15-32.
34. A blood analyzer, characterized in that... include: Memory, used to store programs; A data processor for implementing the method as described in any one of claims 15-32 by executing a program stored in the memory.
Citation Information
Patent Citations
Differential blood count reagent, kit and method of differential blood count
CN101750274A
Cyanine compound, composition containing same and application in cell detection thereof
CN102115456A
Reagent for determining granulophilocyte and determination method
CN1172953A
Hematological analyzer, method for analyzing body fluid and control system thereof
CN101236195A
Blood cell detection reagent, blood cell processing method and blood cell identification method
CN104749144A
